On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
-
BUSINESS Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
-
REGULATORY Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
March 25, 2026
-
REGULATORY Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
March 24, 2026
-
BUSINESS Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
March 23, 2026
-
BUSINESS Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
-
BUSINESS Incyte Looks to More Than Double International Business by 2030: CEO
March 18, 2026
-
REGULATORY Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
-
BUSINESS BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
March 17, 2026
-
BUSINESS SSP Appoints Yoko Motoshima as New President
March 16, 2026
-
BUSINESS PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
-
BUSINESS Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
-
REGULATORY Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
-
REGULATORY Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
-
ACADEMIA CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
-
BUSINESS Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
-
REGULATORY Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
-
BUSINESS Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
-
REGULATORY Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026
-
REGULATORY Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
March 6, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…